First AD

Second AD

Seladelpar for Treatment of PBC

Video content above is prompted by the following:

Could you discuss the long-term data of recently FDA-approved PPAR-δ agonist seladelpar?

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Video Series

Expanding Treatment Options for Primary Biliary Cholangitis with Novel Therapies

Seladelpar, a PPAR-δ agonist, has shown promising long-term efficacy and safety in treating primary biliary cholangitis (PBC). Recent data from clinical trials indicate sustained improvements in liver biochemistry and symptom relief over extended periods. The drug's mechanism involves modulating lipid metabolism and inflammation, which are crucial in PBC management. Seladelpar's safety profile remains favorable, with minimal adverse effects reported. These findings support its potential as a viable therapeutic option for PBC patients, offering an alternative to existing treatments and addressing unmet clinical needs.

The panel of experts review the long-term data on the recently FDA-approved PPAR-δ agonist seladelpar for primary biliary cholangitis (PBC), focusing on its efficacy, safety, and impact on liver biochemistry markers over time.